IL-2 antibody induction and the outcome of pediatric renal transplants.
Garcia
C D
CD
Fundação Faculdade Federal de Ciências Médicas, Santa Casa Hospital, Porto Alegre, Brazil. cdgarcia@terra.com.br
Barros
V R
VR
Schneider
L
L
Alves
M D
MD
Silveira
C G
CG
Garcia
V D
VD
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000917:Antibody Formation / Q000187:drug effects; D000077552:Basiliximab; D002648:Child; D003404:Creatinine / Q000097:blood; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000473:pathology; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007376:Interleukin-2 / Q000096:biosynthesis / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D011183:Postoperative Complications / Q000821:virology; D011993:Recombinant Fusion Proteins; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D003404:Creatinine; D000077561:Daclizumab